TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells

Zoltan Wiener, Barbara Kohalmi, Peter Pocza, Judit Jeager, Gergely Tolgyesi, S. Tóth, Eva Gorbe, Z. Papp, A. Falus

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Many studies detect elevated numbers of mast cells in tumors, but it is still controversial whether they are beneficial or detrimental for tumor cells. Furthermore, many tumors, such as melanomas, produce large quantities of transforming growth factor (TGF)-β and during tumorigenesis the apoptotic and growth-inhibitory effects of TGF-βs are lost. Based on these data we investigated the gene expression changes in TGF-βI-treated human mast cells with DNA microarray and detected 45 differentially regulated genes, among them T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). As the major sources of TIM-3 ligand galectin-9 are not tumor cells, but rather mast cells, this raises the possibility of an autocrine mechanism resulting in local immunosuppression through the elevated TIM-3 expression by TGF-βI. Interestingly, not only melanoma tissue sections contained TIM-3-positive mast cells, but we detected this protein also in melanoma cells. Furthermore, TIM-3 was expressed in both WM35 and HT168-M1 melanoma cell lines at a higher level than in isolated epidermal melanocytes, which can contribute to the lower adhering capacity of tumor cells. In conclusion, the immunoregulatory molecule TIM-3 in TGF-β-stimulated mast cells and melanoma cells may support the survival of this tumor type.

Original languageEnglish
Pages (from-to)906-914
Number of pages9
JournalJournal of Investigative Dermatology
Volume127
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Mast Cells
Transforming Growth Factor beta
Transforming Growth Factors
Tumors
Melanoma
Cells
Neoplasms
Galectins
Galectin 3
T-cells
Melanocytes
Mucins
Microarrays
Oligonucleotide Array Sequence Analysis
Gene expression
Immunosuppression
Immunoglobulins
Carcinogenesis
Proteins
Genes

ASJC Scopus subject areas

  • Dermatology

Cite this

TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. / Wiener, Zoltan; Kohalmi, Barbara; Pocza, Peter; Jeager, Judit; Tolgyesi, Gergely; Tóth, S.; Gorbe, Eva; Papp, Z.; Falus, A.

In: Journal of Investigative Dermatology, Vol. 127, No. 4, 04.2007, p. 906-914.

Research output: Contribution to journalArticle

Wiener, Zoltan ; Kohalmi, Barbara ; Pocza, Peter ; Jeager, Judit ; Tolgyesi, Gergely ; Tóth, S. ; Gorbe, Eva ; Papp, Z. ; Falus, A. / TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. In: Journal of Investigative Dermatology. 2007 ; Vol. 127, No. 4. pp. 906-914.
@article{701682171142429597980926d391e486,
title = "TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells",
abstract = "Many studies detect elevated numbers of mast cells in tumors, but it is still controversial whether they are beneficial or detrimental for tumor cells. Furthermore, many tumors, such as melanomas, produce large quantities of transforming growth factor (TGF)-β and during tumorigenesis the apoptotic and growth-inhibitory effects of TGF-βs are lost. Based on these data we investigated the gene expression changes in TGF-βI-treated human mast cells with DNA microarray and detected 45 differentially regulated genes, among them T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). As the major sources of TIM-3 ligand galectin-9 are not tumor cells, but rather mast cells, this raises the possibility of an autocrine mechanism resulting in local immunosuppression through the elevated TIM-3 expression by TGF-βI. Interestingly, not only melanoma tissue sections contained TIM-3-positive mast cells, but we detected this protein also in melanoma cells. Furthermore, TIM-3 was expressed in both WM35 and HT168-M1 melanoma cell lines at a higher level than in isolated epidermal melanocytes, which can contribute to the lower adhering capacity of tumor cells. In conclusion, the immunoregulatory molecule TIM-3 in TGF-β-stimulated mast cells and melanoma cells may support the survival of this tumor type.",
author = "Zoltan Wiener and Barbara Kohalmi and Peter Pocza and Judit Jeager and Gergely Tolgyesi and S. T{\'o}th and Eva Gorbe and Z. Papp and A. Falus",
year = "2007",
month = "4",
doi = "10.1038/sj.jid.5700616",
language = "English",
volume = "127",
pages = "906--914",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells

AU - Wiener, Zoltan

AU - Kohalmi, Barbara

AU - Pocza, Peter

AU - Jeager, Judit

AU - Tolgyesi, Gergely

AU - Tóth, S.

AU - Gorbe, Eva

AU - Papp, Z.

AU - Falus, A.

PY - 2007/4

Y1 - 2007/4

N2 - Many studies detect elevated numbers of mast cells in tumors, but it is still controversial whether they are beneficial or detrimental for tumor cells. Furthermore, many tumors, such as melanomas, produce large quantities of transforming growth factor (TGF)-β and during tumorigenesis the apoptotic and growth-inhibitory effects of TGF-βs are lost. Based on these data we investigated the gene expression changes in TGF-βI-treated human mast cells with DNA microarray and detected 45 differentially regulated genes, among them T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). As the major sources of TIM-3 ligand galectin-9 are not tumor cells, but rather mast cells, this raises the possibility of an autocrine mechanism resulting in local immunosuppression through the elevated TIM-3 expression by TGF-βI. Interestingly, not only melanoma tissue sections contained TIM-3-positive mast cells, but we detected this protein also in melanoma cells. Furthermore, TIM-3 was expressed in both WM35 and HT168-M1 melanoma cell lines at a higher level than in isolated epidermal melanocytes, which can contribute to the lower adhering capacity of tumor cells. In conclusion, the immunoregulatory molecule TIM-3 in TGF-β-stimulated mast cells and melanoma cells may support the survival of this tumor type.

AB - Many studies detect elevated numbers of mast cells in tumors, but it is still controversial whether they are beneficial or detrimental for tumor cells. Furthermore, many tumors, such as melanomas, produce large quantities of transforming growth factor (TGF)-β and during tumorigenesis the apoptotic and growth-inhibitory effects of TGF-βs are lost. Based on these data we investigated the gene expression changes in TGF-βI-treated human mast cells with DNA microarray and detected 45 differentially regulated genes, among them T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). As the major sources of TIM-3 ligand galectin-9 are not tumor cells, but rather mast cells, this raises the possibility of an autocrine mechanism resulting in local immunosuppression through the elevated TIM-3 expression by TGF-βI. Interestingly, not only melanoma tissue sections contained TIM-3-positive mast cells, but we detected this protein also in melanoma cells. Furthermore, TIM-3 was expressed in both WM35 and HT168-M1 melanoma cell lines at a higher level than in isolated epidermal melanocytes, which can contribute to the lower adhering capacity of tumor cells. In conclusion, the immunoregulatory molecule TIM-3 in TGF-β-stimulated mast cells and melanoma cells may support the survival of this tumor type.

UR - http://www.scopus.com/inward/record.url?scp=33947224207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947224207&partnerID=8YFLogxK

U2 - 10.1038/sj.jid.5700616

DO - 10.1038/sj.jid.5700616

M3 - Article

C2 - 17096021

AN - SCOPUS:33947224207

VL - 127

SP - 906

EP - 914

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 4

ER -